New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
19:12 EDTSGMOSangamo BioSciences upgraded to Overweight from Underweight at Piper Jaffray
Piper Jaffray upgraded Sangamo BioSciences two notches to Overweight from Underweight and raised its price target for shares to $10 from $4 after assuming coverage of the stock. Piper says the company has a broad gene therapy platform with increasing visibility.
News For SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:10 EDTSGMOPiper Jaffray to hold a symposium
Subscribe for More Information
May 18, 2015
07:06 EDTSGMOSangamo presents new data from proprietary ZFP therapeutic programs
Subscribe for More Information
May 14, 2015
09:11 EDTSGMOSangamo updates HIV and cancer candidates results
Sangamo BioSciences announced clinical and preclinical data from several ZFP Therapeutic programs and collaborations demonstrating new evidence of viral control in HIV/AIDS. Two trials of the company's ZFP Therapeutic, SB-728-T, which is being developed as a potential 'functional cure' for HIV/AIDS, demonstrated the effect of SB-728-T treatment on both viral load control and HIV reservoir reduction in HIV-infected subjects. Data were also presented demonstrating the successful incorporation of ZFN-mediated genome editing into an existing clinical scale production method to improve the anti-tumor activity of a tumor infiltrating lymphocyte-based therapeutic for melanoma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use